New understanding of aconitine hydrolysis pathway: Isolation, identification and toxicity evaluation based on intermediate products

He, Ya-Nan; Lu-meng, Chen; Liu, Yu; Hu, Qi; Cao, Zhixing; Li, Han; Run-chun, Xu; Yang, Ming–Hsuan; Yin, Tian; Zhang, Dingkun

doi:10.1016/j.arabjc.2022.104255

Cited by 1 publication

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[27] The analgesic effects of AR extract have been well established in previous studies, with ongoing research investigating its therapeutic potential. [28,29] As highlighted in numerous studies [30][31][32] , it is essential to eliminate the presence of the toxic compound Aconitine while simultaneously increasing the concentration of the effective compound Aconine. Initially, our study focused on converting Aconitine to Aconine through a heating process, making it safe for human use.…”

Section: Analysis Of Heated Aconite Root Extractmentioning

confidence: 99%

Transdermal Delivery of Polymeric Nanoparticles Containing Aconite Root for the Treatment of Chemotherapy‐Induced Peripheral Neuropathy

Park,

Hwang,

Kim

2024

Advanced NanoBiomed Research

View full text Add to dashboard Cite

Chemotherapy‐induced peripheral neuropathy (CIPN) poses challenges like pain and numbness, necessitating innovative treatments due to current limitations. Conventional approaches, relying on pain relief medications and dose adjustments, fall short in addressing neurotoxicity, resulting in inadequate pain relief and undesired effects. Aconite root (AR), a medicinal herb withcenturies of use against various diseases, contains a compound named Aconine, which alleviates pain by blocking specific neural channels. However, AR also contains Aconitine, a toxic substance hydrolyzed into nontoxic Aconine through heating. Herein, hyaluronate‐poly(lactic‐co‐glycolic acid) nanoparticles (HA‐PLGA/AR NPs) encapsulating Aconine are fabricated, enabling controlled release, protection, and transdermal delivery, enhancing therapeutic outcomes. High‐performance liquid chromatography identifies optimal Aconine content after 48 h of AR boiling, with minimal neural toxicity confirmed. Characterization via transmission electron microscopy, dynamic light scattering, and in vitro assays demonstrates superior drug release by HA‐PLGA/AR NPs, establishing effective transdermal Aconine delivery. In an in vitro CIPN model with paclitaxel (PTX)‐treated PC12 cells, HA‐PLGA/AR NPs stimulate enhanced neurite growth, validating their localized analgesic impact on CIPN and suggesting potential symptom alleviation. Taken together, HA‐PLGA/AR NPs offer a promising strategy for controlled transdermal Aconine delivery, potentially alleviating CIPN and addressing various neuropathies and diseases.

show abstract